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Abstract Studies of mutants of the yeast Saccharomyces revisiae have led to the identification of genes required for high affinity iron uptake. 
Reduction of iron (III) outside the cell is accomplished by means of reductases ncoded by FRE1 and FRE2, homologues of the gp91-phox component 
of the oxygen reductase of human granulocytes. High affinity iron (II) transport from the exterior to the interior of the cell occurs by means of a 
transport system that has not been molecularly characterized. However, the transport process requires the activity of a copper-containing oxidase 
encoded by FET3. The amino acid sequence of this protein resembles other multi-copper oxidases, including mammalian ceruloplasmin. High affinity 
copper uptake mediated by the copper transport protein encoded by CTR1 is required to provide the FET3 protein with copper, and thus copper 
uptake is indirectly required for ferrous iron uptake. These genetic elements of yeast and their elationships may be conserved in complex eukaryotic 
organisms. 
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1. Introduction 
The universal requirement that organisms have for iron pre- 
sents a variety of challenges, many of which are manifestations 
of the problems produced by oxygen. The insolubity of iron 
(III) and the potential toxicity of iron (II) in the presence of 
oxygen demand elaborate biological responses to provide or- 
ganisms with sufficient iron while preventing against iron toxic- 
ity [1]. In this review, we will focus on recent work characteriz- 
ing specific mechanisms for iron acquisition in the yeast 
Saccharomyces cerevisiae. The oxidation of iron (II) by molec- 
ular oxygen results in a decrease in solubility at neutral pH of 
sixteen orders of magnitude to levels that are likely to be incom- 
patible with the needs of cells [2]. Organisms have resolved this 
problem by utilizing two distinct strategies (Fig. 1). The first, 
used by most prokaryotes and some eukaryotes, involves the 
synthesis and secretion of low molecular weight ferric chelators, 
or siderophores, which effectively solubilize nvironmental iron 
(III) [3]. The ferric-siderophore complexes are specifically 
transported into the cell. Release of the iron from the sidero- 
phore may occur by a variety of mechanisms often involving 
iron (III) reduction inside the cell [4,5]. Many eukaryotes, in- 
cluding S. cerevisiae, do not synthesize siderophores [2] but 
rather appear to transport ferrous iron from the environment 
across the plasma membrane to the cell interior. In order to 
achieve this, an organism must have a mechanism to reduce 
environmental iron (III) to iron (II). The role of ferric reduc- 
tases in iron uptake has long been postulated [6] and surface 
reductases have been assayed in a variety of cells, including 
Saccharomyces cerevisiae [6-10]. The description of an exter- 
nally directed ferric reductase activity in this organism which 
could be repressed by excess iron further suggested a connec- 
tion between this activity and regulated iron assimilation [11]. 
Demonstration of the link between physiological iron uptake 
and the measured biochemical ctivity required both the molec- 
ular identification of one or more surface reductases and ge- 
netic experiments o establish the importance of such reduc- 
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tases in iron assimilation. S. cerevisiae has proved to be a 
tractable ukaryotic organism amenable to the genetic analysis 
of biochemical pathways, and recent efforts have reinforced 
this approach for iron metabolism. 
2. Identification of a ferric reductase 
Using a colorimetric assay capable of detecting surface re- 
ductase activity of single colonies of S. cerevisiae, a mutant was 
identified that lacked 90% of such surface ferric reductase activ- 
ity [12]. The gene responsible for the defect in the mutant, 
termed FRE1, was cloned by complementation a d character- 
ized. Deletion of the FRE1 gene in several strain backgrounds 
resulted in a decreased level of cell-surface reductase activity, 
similar to the defect in the original mutant. Importantly, the 
FRE1 null strains were also severely defective in the capacity 
to assimilate radioactive iron presented to the cells as a ferric 
salt. Furthermore, expression of FRE1 was found to be tran- 
scriptionally controlled by the concentration of iron in the 
growth medium. Induction by iron deprivation and repression 
by iron sufficiency was mediated, in large part, through a small 
region of the 5' flanking region of the FRE1 gene [13]. Thus, 
FRE1 was required for ferric iron uptake and its expression was 
regulated in a manner consistent with a homeostatically con- 
trolled component of an iron uptake system. 
3. A family of plasma membrane reductases 
Yeast strains with complete deletion of the FRE1 open read- 
ing frame exhibited residual surface ferric reductase activity 
[13]. This residual activity varied considerably depending on the 
strain background and growth conditions, but its existence 
raised the possiblity that there were additional ferric reductase 
gene(s) in S. cerevisiae. That this residual activity, not attribut- 
able to FRE1, might also be involved in physiologic iron uptake 
was suggested by the fact that the activity was regulated by iron 
in a manner similar to the regulation of FRE1 [13]. Recently, 
in the course of the sequencing of chromosome XI of S. cere- 
visiae, an open reading frame was identified with low but signif- 
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Fig. 1. Transport/reduction. Bacteria nd some fungi are capable of transporting ferric iron (triangles with the symbol III) from the enviroment to 
the cell interior prior to reduction to ferrous iron (squares with the symbol II) which occurs inside the cell. The lower diagram depicts the siderophore 
(circle with S) binding to iron (III) outside the cell and being transported to the cell interior via the siderophore ceptor. A cytosolic reductase (oval 
labeled reductase) is required to complete the iron delivery, stripping the iron from the siderophore and yielding cytosolic iron (II). Reduction/ 
transport: In the yeast Saccharomcyces revisiae, iron (III) is reduced outside the cell by a membrane bound externally directed reductase (oval abeled 
reductase) and transported tothe cell interior by means of a molecularly distinct ferrous transporter (cylinder). 
icant amino acid homology with FRE1 [14]. The gene, termed 
FRE2, was found to be regulated by iron in a manner similar 
to FRE1, although there were some differences between FRE1 
and FRE2 in the kinetics of the regulation and the effects of 
growth phase. Deletion of FRE2 and FRE1 resulted in a mutant 
strain with essentially undetectable iron regulated surface re- 
ductase activity. Furthermore, the double deletion strain, while 
viable, displayed a severely impaired ability to grow in low-iron 
media conditions [15]. The fission yeast Schizosaccharomyces 
pombe is distantly related to Saccharomyces cerevisiae and yet 
appears to assimilate iron through a mechanism analogous to 
S. cerevisiae. In S. pombe, a homologue of FRE1, termed frpl  +, 
was identified by following an approach similar to the approach 
used in S. cerevisiae. The colony assay was used to identify a 
reductase-negative mutant, and the mutant was complemented 
with a genomic library. The genefrpl ÷ was found to be required 
for ferric iron assimilation and was shown to be regulated by 
iron, like FRE1 and FRE2 [16]. 
Examination of the amino acid sequences of Frelp and and 
Fre2p revealed a marked similarity of their hydropathy plots 
[15]. Each has an N-terminal eader sequence and multiple 
predicted membrane spanning domains. As originally de- 
scribed for Fre lp and Frp lp  [16], Fre2p demonstrates amino 
acid sequence similarity of a low but significant level to the 
gp91-phox subunit of the respiratory burst oxidase of human 
granulocytes (reviewed in [17]). The latter functions in the 
transfer of reducing equivalents from cytoplasmic NADPH 
across the plasma membrane to molecular 02 as the acceptor. 
The human oxygen reductase and the yeast ferric reductases 
resemble one another in the direction of movement of reducing 
equivalents from cytoplasm to an extracellular cceptor and the 
single-electron nature of the reduction. Moreover, contained 
within the primary sequences of these reductases are conserved 
amino acid motifs that may be critical to their function, includ- 
ing predicted NADPH and ravin adenine nudeotide binding 
sites [18,19]. These amino acid homologies, coupled with the 
genetic analysis, suggests that Frelp, Fre2p and Frp lp  are 
likely to be structural elements of surface reductases. 
4. The transport of ferrous iron 
Evidence has accumulated suggesting that organisms may be 
capable of acquiring iron (II) from the environment without he 
mediation of a siderophore [20]. The identification of the 
S. cerevisiae FRE1 gene made possible the demonstration f a 
distinct ferrous uptake mechanism acting downstream of the 
reductase in the uptake pathway of environmental iron. Com- 
plete deletion of the FRE1 gene in several genetic backgrounds 
resulted in severely deficient uptake of iron (III) but unim- 
paired (and even elevated) uptake of iron (II). Biochemical 
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Fig. 2. (A) The objective of the two selection schemes i to prevent the 
growth of cells able to take up iron. In the FRE1-HIS3 selection (A, 
top panel), iron (dark triangle) entering acell by means of the normal 
high-affinity uptake pathway leads to repression of the FRE1 promoter, 
and histidine auxotrophy results. Since His3 protein is not synthesized 
in this strain, which lacks an endogenous HIS3 gene, it will not grow 
under conditions of sufficient iron and no added histidine. Mutants 
lacking normal iron uptake abrogate repression of the FRE1-HIS3 
fusion. For the streptonigran (SNG) selection (A, lower panel), the drug 
is taken into the cell where it may combine with cytosolic iron to create 
an iron-drug complex injurious to DNA and other macromolecules. 
Mutants lacking iron uptake will escape the toxic effects of the drug. 
(B) The selection allows mutants with defects in iron uptake to grow 
(filled circles) while the wild-type background cells (empty circles) do 
not grow). (C) When the mutants are evaluated for the ability to grown 
under conditions of low available iron, many exhibit impaired growth. 
studies confirmed the existence of a high-affinity iron (II) up- 
take system that was saturable and specific for iron. While both 
the reductase and the ferrous transport system were found to 
be repressed by iron, the two activities were also distinctly 
regulated, especially vis-a-vis cell growth [21]. 
Two recently reported genetic approaches have been used to 
identify genes involved in mediating iron (II) transport (Fig. 2). 
In one approach, the iron-regulated FRE1 promoter was used 
to drive expression of the His3 protein in a HIS3-deleted strain 
[22]. For this strain, the addition of iron to the medium resulted 
in auxotrophy for histidine due to the transcriptional repression 
of the FRE1-HIS3 fusion gene. Spontaneously arising mutants 
were isolated that were able to overcome the iron-dependent 
histidine auxotrophy. Some of these proved to be deficient 
in{ll}high-affinity ferrous iron uptake. An alternative selec- 
tion scheme [23], employed streptonigrin to select mutants re- 
sistant o the toxic effects of the drug. Since the toxicity of this 
drug is dependent upon the ability of cells to accumulate iron, 
this approach also identified mutants defective in iron uptake. 
Using the FRE1-HIS3 selection, six distinct genes were iden- 
tiffed that when mutated resulted in histidine prototrophy in the 
presence of iron. The most commonly selected mutations, re- 
sulting in the loss of function of the CTR1 gene, completely 
abrogated high-affinity iron (II) uptake. The protein product 
of this gene, predicted to have a core molecular weight of 46 
kDa, was found to migrate at 100-105 kDa on an SDS poly- 
acrylamide gel, most likely due to extensive modification by 
O-linked sugars [24]. The predicted amino acid sequence of the 
protein suggested that it would traverse the membrane 3 times, 
and it has been localized to the plasma membrane [22], where 
it exists as a homooligomer [24]. Its unusual amino terminal 
domain, which is most likely facing the outside of the cell, 
contains multiple repeats of an amino acid motif that has re- 
cently been identified in a number of copper-binding proteins 
(MXXM, where X is likely to be a serine or a negatively 
charged amino acid). This observation prompted the specific 
assessment of the role of this protein in copper transport. 
S. cerevisiae was found to possess a high-affinity, specific op- 
per uptake system requiring CTR1. Thus, mutants of CTR1 
were deficient in the high-affinity uptake of both copper and 
iron. However, the addition of high concentrations of copper 
to the medium, presumably able to gain entry to the cell via a 
low-affinity uptake pathway, resulted in the restoration of 
high-affinity ferrous iron transport, whereas the converse was 
not true; iron loading could not restore high-affinity copper 
uptake [24]. 
A likely explanation for this effect was provided by the iden- 
tification of the FET3 gene [23]. The cloning of the FET3 gene 
and examination of the predicted amino acid sequence revealed 
a protein predicted to traverse the membrane a single time and 
possessing significant homology to ascorbate oxidase and lac- 
case, multi-copper oxidases found in plants. In addition, FET3 
exhibited more distant but still significant homology to ceru- 
loplasmin, a copper-dependent oxidase present in the plasma 
of mammals. Included in the sequences conserved among these 
proteins were motifs believed to be involved in the binding of 
copper. A mutant in the FET3 gene was identified using the 
streptonigrin resistance selection and, like mutants of CTR1, 
was found to lack high-affinity ferrous transport [23]. In con- 
trast to CTR1 mutants, however, FET3 mutants exhibited nor- 
mal copper uptake, and the addition of copper failed to correct 
the defect in high-affinity iron uptake. A strain carrying muta- 
tions of both the CTR1 and FET3 genes lacked the copper 
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Fig. 3. General scheme for iron uptake in Saccharomyces cerevisiae. 
Iron (III) (filled trianges) in the environment is reduced by externally 
directed reductases Frel p and Fre2p (ovals) to iron (II) (filled squares). 
A ferrous transporter (cylinder) which has been characterized only as 
an activity transports he ferrous iron to the cellular interior. This step 
requires copper uptake via the plasma membrane copper transport 
protein, Ctr 1 p, and activity of the putative multi-copper oxidase, Fet3p. 
mediated restoration of high-affinity ferrous uptake. This sug- 
gested that the copper requirement for high-affinity ferrous 
iron uptake might relate to the need to supply copper to the 
Fet3 protein. 
How might Fet3p, a predicted copper-containing oxidase, be 
functioning in the high-affinity uptake of ferrous iron? Answer- 
ing this will require definition of the biochemistry of the Fet3 
protein. Is it, in fact, a copper-containing oxidase? If so, what 
are its physiologic substrates? Critical to any model for the 
function of this protein will be establishing its intracellular 
location and its topology with respect o the membrane. It is 
predicted to have a single transmembrane domain situated near 
its carboxy terminus and following the copper-binding domain. 
The absence of an N-terminal leader sequence does not allow 
us to predict on which side of the membrane the predicted 
oxidase domain sits. In one model, predicated on the cytosolic 
location of the oxidase, the iron (II) transport is completed by 
being coupled to the cytosolic oxidation of the metal back to 
the ferric form. Alternatively, if the predicted copper-depend- 
ent oxidase is either in the lumen of the secretory pathway or 
outside the cell, the mode of action is more mysterious. One 
possibility is that the protein provides a signaling system, per- 
haps sensing oxygen or redox state, that is coupled to iron (II) 
transport via the regulated expression or function of a ferrous 
transporter. Such a transporter has not yet been molecularly 
identified. Whatever the mechanism, these studies point to a 
central role for this new member of the family of copper-de- 
pendent multi-functional oxidases in the ability of cells to accu- 
mulate iron via a high-affinity ferrous uptake system (Fig. 3). 
5. Evidence for the generality of the S. cerevisiae model 
The literature on iron transport has provided considerable 
circumstantial evidence suggesting that the mechanisms de- 
scribed for yeast may be conserved in some form in complex 
eukaryotes. Recently, a ferric reductase activity was localized 
to the lumenal surface of intestinal epithelial cells in the mouse. 
This activity was found to correlate with the ability of the cells 
to assimilate environmental iron [25]. The most complete model 
for mammalian transmembrane transport of iron has come 
from the work of Glass and colleagues in their studies on the 
transport of iron out of reticulocyte endosomes. They proposed 
that after the acid-dependent release of iron (III) from transfer- 
rin bound to the transferrin receptor, there is an obligate 
NADPH dependent reduction step to produce iron (II), which 
only then can be transported into the cytoplasm [26-28]. Thus, 
the reduction of iron (III) by membrane-bound reductases may 
be a general feature of eukaryotic iron transport. Finally, the 
connection between copper and iron transport observed for 
S. cerevisiae may have a parallel in mammals. Studies on cop- 
per-deficient swine in the 1950s suggested that a deficiency of 
serum ceruloplasm resulted in the failure to transport iron 
across membranes [29-31]. In addition, studies with mammal- 
ian cells in culture have suggested that copper enhances trans- 
ferrin-mediated iron delivery into the cytosol [32]. While many 
of the details of molecular i on metabolism in the simple eukar- 
yore S. cerevisiae remain to be worked out, it is hoped that these 
studies may provide insights into conserved pathways in com- 
plex organisms uch as man. 
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